Volume 6.38 | Oct 7

Mesenchymal Cell News 6.38 October 7, 2014
Mesenchymal Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MESCN on Twitter
Niche-Dependent Regulations of Metabolic Balance in High-Fat Diet Induced Diabetic Mice by Mesenchymal Stromal Cells
Scientists demonstrate that, in mice continuously feed with high-fat diet and developed non-insulin dependent diabetes, two episodes of systemic mesenchymal stromal cell transplantations effectively improve the glucose tolerance, blood sugar homeostasis and reduce the body weight through targeting pancreas and insulin-sensitive tissues and organs via site-specific mechanisms. [Diabetes] Abstract
25% Off First Order: MNCs, purified cells and more
PUBLICATIONS (Ranked by impact factor of the journal)
Differential Efficacy of Human Mesenchymal Stem Cells Based on Source of Origin
The authors provided insight into the optimum source of mesenchymal stem cells (MSCs) and identified in vitro assays that predict in vivo efficacy. They derived MSCs from four umbilical cords, four healthy bone marrows (BMs), and four lupus BMs. [J Immunol] Abstract

Role of Gamma-Secretase in Human Umbilical-Cord Derived Mesenchymal Stem Cell Mediated Suppression of NK Cell Cytotoxicity
Scientists studied the interaction of umbilical cord derived (UC)-mesenchymal stem cells (MSCs) with unstimulated allogeneic natural killer (NK) cells. UC-MSCs could potently suppress NK cell cytotoxicity in overnight cultures via the soluble factors. [Cell Commun Signal] Abstract | Full Article

Promoting the Recovery of Injured Liver with PHBVHHx Scaffolds Loaded with Umbilical Cord-Derived Mesenchymal Stem Cells
Poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) (PHBVHHx) scaffolds loaded with mesenchymal stem cells that were isolated from umbilical cord were transplanted into liver-injured mice. Liver morphology improved after 30 days of transplantation and looked similar to normal liver. [Tissue Eng Part A] Abstract

Corticosterone Mediates the Inhibitory Effect of Restraint Stress on the Migration of Mesenchymal Stem Cell to Carbon Tetrachloride-Induced Fibrotic Liver by Down-Regulating CXCR4/7 Expression
Investigators employed a carbon tetrachloride-induced mouse liver fibrosis model to investigate whether constraint stress affects the migration of MSCs to fibrotic liver. [Stem Cells Dev] Abstract

Variations of Chromosomes 2 and 3 Gene Expression Profiles among Pulmonary Telocytes, Pneumocytes, Airway Cells, Mesenchymal Stem Cells and Lymphocytes
Researchers compared gene expression profiles of pulmonary telocytes, mesenchymal stem cells, fibroblasts, alveolar type II cells, airway basal cells, proximal airway cells, CD8+ T cells from bronchial lymph nodes, and CD8+ T cells from lungs. [J Cell Mol Med] Full Article

MSC Therapy Attenuates Obliterative Bronchiolitis after Murine Bone Marrow Transplant
Administration of mesenchymal stromal cells (MSCs) was evaluated for the ability to ameliorate obliterative bronchiolitis in mice using an established allogeneic bone marrow transplant model. [PLoS One] Full Article

Effects of Different Mesenchymal Stromal Cell Sources and Delivery Routes in Experimental Emphysema
Researchers assessed whether the effects of mesenchymal stromal cells (MSC) on lung inflammation and remodeling in experimental emphysema would differ according to MSC source and administration route. [Respir Res] Full Article

Roles of FGF-2 and TGF-Beta/FGF-2 on Differentiation of Human Mesenchymal Stem Cells towards Nucleus Pulposus-Like Phenotype
Mesenchymal stem cells were cultured in conditioned medium containing fibroblast growth factor (FGF)-2 or transforming growth factor (TGF)-beta/FGF-2, and compared with basal or TGF-beta medium. The groups with FGF-2 showed the increase of cell proliferation. [Growth Factors] Abstract

Combining Xanthan and Chitosan Membranes to Multipotent Mesenchymal Stromal Cells as Bioactive Dressings for Dermo-Epidermal Wounds
Investigators assessed the applicability of bioactive dressings associating dense and porous chitosan-xanthan membranes to multipotent mesenchymal stromal cells for the treatment of skin wounds. [J Biomater Appl] Abstract

The Temporal Expression of Estrogen Receptor Alpha-36 and Runx2 in Human Bone Marrow Derived Mesenchymal Stromal Cells during Osteogenesis
Scientists investigated the temporal expression of estrogen receptor-α36 and ascertain its functional relevance during osteogenesis in human bone marrow derived mesenchymal stromal cells. [Biochem Biophys Res Commun] Abstract

SmartDish™ with STEMgrid™-6 for Accurate Counting of Hematopoietic CFU Assays
Mesenchymal Stem Cells as a Potential Therapeutic Tool for Spinocerebellar Ataxia
The authors introduce the therapeutic influence of mesenchymal stem cells (MSCs) on each mouse model for cerebellar ataxia and the possible mechanisms underlying the action of MSCs. They also introduce studies on the safety and effectiveness of umbilical cord MSCs for patients with spinocerebellar ataxia. [Cerebellum] Abstract

Epigenetic Approaches to Regeneration of Bone and Cartilage from Stem Cells
Features of embryonic stem cells and adult stem cells, epigenetics and chromatin structure, as well as epigenetic mechanisms, such as chromatin remodeling, DNA methylation and histone modifications, polycomb group proteins and microRNAs are described. [Expert Opin Biol Ther] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.
Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan
Mesoblast Limited reported that its Japanese partner, JCR Pharmaceuticals Co Ltd, has filed with the Japanese Pharmaceuticals and Medical Devices Agency to receive approval for manufacturing, marketing, and product registration of the allogeneic or “off-the-shelf” mesenchymal stem cell product JR-031 for the treatment of acute graft versus host disease in children and adults. [Mesoblast Limited] Download Press Release

FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALS
BrainStorm Cell Therapeutics Inc. announced that the United States Food and Drug Administration (FDA) has designated NurOwn™ as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS). NurOwn™ consists of autologous mesenchymal stem cells that have been induced to secrete neurotrophic factors, and is currently being studied in a randomized, double-blind, placebo-controlled Phase II clinical trial in ALS patients. [BrainStorm Cell Therapeutics Inc. (PR Newswire Association LLC.)] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUOR™ can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW CIRM Showcase: Accelerating Stem Cell Treatments to Patients
November 5, 2014
San Francisco, United States

NEW Global Controls in Stem Cells
November 5-7, 2014
Singapore, Singapore

Visit our events page to see a complete list of events in the mesenchymal cell community.
NEW Research Associate Position – Skeletal Research Center (Case Western Reserve University)

NEW PhD Studentship – Biophysics and Mechanics of Stem Cells (Queen Mary University of London)

Postdoctoral Position – Epigenetics in Aging, Osteoporosis and Stem Cells (Aachen University Medical School)

Postdoctoral Fellow – Chondrocyte Differentiation and Its Role in Osteoarthritis (NYU Langone Medical Center)

Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Postdoctoral Fellowship – Epigenetic Regulation of Cell Fate and Metabolism (University Medical Center Freiburg)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Mesenchymal Stromal/Stem Cell Scientist (UHN Arthritis Program)

Scientist – Mesenchymal Stem and Progenitor Cell Biology (STEMCELL Technologies Inc.)

Scientist – Myogenic Progenitor Cell Biology (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mesenchymal Cell News: Archives | Events | Contact Us